Eradicating the Roots: Advanced Therapeutic Approaches Targeting Breast Cancer Stem Cells

2020 ◽  
Vol 26 (17) ◽  
pp. 2009-2021 ◽  
Author(s):  
Lili He ◽  
Anran Yu ◽  
Li Deng ◽  
Hongwei Zhang

Accumulating evidences have demonstrated that the existence of breast cancer-initiating cells, which drives the original tumorigenicity, local invasion and migration propensity of breast cancer. These cells, termed as breast cancer stem cells (BCSCs), possess properties including self-renewal, multidirectional differentiation and proliferative potential, and are believed to play important roles in the intrinsic drug resistance of breast cancer. One of the reasons why BCBCs cause difficulties in breast cancer treating is that BCBCs can control both genetic and non-genetic elements to keep their niches safe and sound, which allows BCSCs for constant self-renewal and differentiation. Therapeutic strategies designed to target BCSCs may ultimately result in effective interventions for the treatment of breast cancer. Novel strategies including nanomedicine, oncolytic virus therapy, immunotherapy and induced differentiation therapy are emerging and proved to be efficient in anti-BCSCs therapy. In this review, we summarized breast tumor biology and the current challenges of breast cancer therapies, focused on breast cancer stem cells, and introduced promising therapeutic strategies targeting BCSCs.

Cancers ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 54
Author(s):  
Margaret L. Dahn ◽  
Paola Marcato

Cancer stem cells (CSCs) are functionally defined in our laboratories by their impressive tumor-generating and self-renewal capacity; clinically, CSCs are of interest because of their enhanced capacity to evade conventional therapies [...]


2016 ◽  
Vol 23 (4) ◽  
pp. 83-89 ◽  
Author(s):  
X Sun ◽  
C Xu ◽  
S-C Tang ◽  
J Wang ◽  
H Wang ◽  
...  

2010 ◽  
Vol 126 (2) ◽  
pp. 355-364 ◽  
Author(s):  
Alejandro Vazquez-Martin ◽  
Cristina Oliveras-Ferraros ◽  
Sonia Del Barco ◽  
Begoña Martin-Castillo ◽  
Javier A. Menendez

Theranostics ◽  
2020 ◽  
Vol 10 (21) ◽  
pp. 9458-9476 ◽  
Author(s):  
Lutao Du ◽  
Xiaoyan Liu ◽  
Yidan Ren ◽  
Juan Li ◽  
Peilong Li ◽  
...  

EMBO Reports ◽  
2016 ◽  
Vol 17 (7) ◽  
pp. 1081-1081 ◽  
Author(s):  
Ivan Bahena‐Ocampo ◽  
Magali Espinosa ◽  
Gisela Ceballos‐Cancino ◽  
Floria Lizarraga ◽  
Denise Campos‐Arroyo ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-14 ◽  
Author(s):  
Wen-Ying Liao ◽  
Chih-Chuang Liaw ◽  
Yuan-Chao Huang ◽  
Hsin-Ying Han ◽  
Hung-Wei Hsu ◽  
...  

Breast cancer stem cells (CSCs) are highly tumorigenic and possess the capacity to self-renew. Recent studies indicated that pluripotent geneNANOGinvolves in regulating self-renewal of breast CSCs, and expression of NANOG is correlated with aggressiveness of poorly differentiated breast cancer. We initially confirmed that breast cancer MCF-7 cells expressed NANOG, and overexpression of NANOG enhanced the tumorigenicity of MCF-7 cells and promoted the self-renewal expansion of CD24−/lowCD44+CSC subpopulation. In contrast, knockdown of NANOG significantly affected the growth of breast CSCs. Utilizing flow cytometry, we identified five cyclohexylmethyl flavonoids that can inhibit propagation of NANOG-positive cells in both breast cancer MCF-7 and MDA-MB231 cells. Among these flavonoids, ugonins J and K were found to be able to induce apoptosis in non-CSC populations and to reduce self-renewal growth of CD24−/lowCD44+CSC population. Treatment with ugonin J significantly reduced the tumorigenicity of MCF-7 cells and efficiently suppressed formation of mammospheres. This suppression was possibly due to p53 activation and NANOG reduction as either addition of p53 inhibitor or overexpression of NANOG can counteract the suppressive effect of ugonin J. We therefore conclude that cyclohexylmethyl flavonoids can possibly be utilized to suppress the propagation of breast CSCs via reduction of NANOG.


Sign in / Sign up

Export Citation Format

Share Document